Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
    • AGM Invitations
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team

AstraZeneca

1,792.50 SEK

+0.67 %

Less than 1K followers

AZN

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data

Quarter data

Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for AstraZeneca

Q3/24Q4/242024Q1/25Q2/25Q3/25Q4/252025
Revenue136,968.0150,356.8596,387.3130,092.9138,412.8145,353.3142,585.6540,239.6
EBITDA39,611.244,154.9184,090.047,468.446,884.449,105.041,286.6179,126.4
EBIT21,264.620,557.8110,326.135,175.233,585.934,283.527,389.5126,398.4
EBIT-%15.5 %13.7 %18.5 %27.0 %24.3 %23.6 %19.2 %23.4 %
Profit before taxes18,457.616,821.995,855.632,571.129,938.231,039.824,179.7114,064.8
Net income14,469.215,145.777,657.327,965.923,437.424,255.921,420.594,115.9
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.